Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)

12. november 2026 oppdatert av: Merck Sharp & Dohme LLC

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Participants With Rheumatoid Arthritis

Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. Researchers are doing this trial to learn if a trial medicine called MK-8690 can treat symptoms of active RA in people who are taking MTX.

The goal of this study is to learn if MK-8690 works better than placebo to improve RA symptoms.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Fase 2

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has a clinical diagnosis of rheumatoid arthritis (RA) and fulfillment of 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria
  • Has active disease defined as ≥6 tender joints (based on 68 joints) and ≥6 swollen joints (based on 66 joints)
  • Has current treatment with oral or parenteral methotrexate (MTX) therapy
  • Has history of one of the following: a) biologic disease-modifying antirheumatic drug (bDMARD) naïve, or b) bDMARD-inadequate response (IR)/intolerant up to a maximum of 1 class of bDMARD

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has any arthritis with onset before age 17 years or current diagnosis of inflammatory joint disease other than RA (such as, but not limited to, psoriatic arthritis, systemic lupus erythematosus, gout, systemic sclerosis, myositis, pseudogout, etc.), or any other condition that may interfere with the assessment of RA
  • Has a transplanted organ and requires continued systemic immunosuppression
  • Has a history of cancer (except fully treated nonmelanoma skin cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for <5 years before randomization
  • Is known to be infected with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus
  • Has an active infection

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Period 1: MK-8690

Participant will receive MK-8690 subcutaneous (SC) for 12 weeks

Solution for SC injection

Andre navn:
  • PRA052

Background therapy - variable dose strength with route of administration per approved product label

Placebo komparator: Period 1: Placebo

Participant will receive placebo SC for 12 weeks

Background therapy - variable dose strength with route of administration per approved product label

Solution for SC injection

Eksperimentell: Extension Period

After completing Period 1 participants will receive MK-8690 SC for 40 weeks.

Solution for SC injection

Andre navn:
  • PRA052

Background therapy - variable dose strength with route of administration per approved product label

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 12
Tidsramme: Week 12

ACR response is a well-established composite measure used in clinical trials to evaluate clinical response in rheumatoid arthritis (RA). ACR50 response is defined as 50% or greater improvement in tender joint count (TJC) based on 68 joints, swollen joint count (SJC) based on 66 joints, and ≥3 of the 5 remaining components of Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment of Disease Activity (PGA), Patient Global Assessment of Disease Activity (PtGA), Patient Assessment of Pain Severity, and high-sensitivity C-reactive protein (hsCRP). ACR50 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 50% improvement in the composite measure. The percentage of participants achieving ACR50 at Week 12 will be presented.

Week 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants Who Experience One or More Adverse Events (AEs)
Tidsramme: Up to approximately 70 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience 1 or more AEs will be presented.

Up to approximately 70 weeks
Number of Participants Who Discontinue Study Intervention Due to an AE
Tidsramme: Up to approximately 48 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be presented.

Up to approximately 48 weeks
Percentage of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 12
Tidsramme: Week 12

ACR20 response is defined as 20% or greater improvement in TJC based on 68 joints, SJC based on 66 joints, and ≥3 of the 5 remaining components of HAQ-DI, PGA, PtGA, Patient Assessment of Pain Severity, and hsCRP. ACR20 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 20% improvement in the composite measure. The percentage of participants achieving ACR20 at Week 12 will be presented.

Week 12
Percentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 12
Tidsramme: Week 12

ACR70 response is defined as 70% or greater improvement in TJC based on 68 joints, SJC based on 66 joints, and ≥3 of the 5 remaining components of HAQ-DI, PGA, PtGA, Patient Assessment of Pain Severity, and hsCRP. ACR70 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 70% improvement in the composite measure. The percentage of participants achieving ACR70 at Week 70 will be presented.

Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) based on Disease Activity Score 28 Using C-Reactive Protein (DAS28-CRP) at Week 12
Tidsramme: Week 12

The DAS28-CRP is a continuous composite measure of RA activity that includes the following components:

  • TJC (out of a total of 28 joints)
  • SJC (out of a total of 28 joints)
  • hsCRP
  • PtGA The 28 anatomical joints for inclusion in the TJC and SJC scoring are the shoulders, elbows, wrists, first through fifth metacarpophalangeals, second through fifth proximal interphalangeals, thumb interphalangeals, and knees. The DAS28-CRP score ranges from 0 to 10, with higher scores indicating a higher degree of disease activity. LDA is indicated by a DAS28-CRP score of ≤3.2. The percentage of participants achieving LDA at Week 12 will be presented.
Week 12
Change from Baseline in DAS28-CRP
Tidsramme: Baseline and at designated timepoints up to Week 52

The DAS28-CRP is a continuous composite measure of RA activity that includes the following components:

  • TJC (out of a total of 28 joints)
  • SJC (out of a total of 28 joints)
  • hsCRP
  • PtGA The 28 anatomical joints for inclusion in the TJC and SJC scoring are the shoulders, elbows, wrists, first through fifth metacarpophalangeals, second through fifth proximal interphalangeals, thumb interphalangeals, and knees. The DAS28-CRP score ranges from 0 to 10, with higher scores indicating a higher degree of disease activity. The change from Baseline at designated timepoints up to Week 52 in the DAS28-CRP will be presented.
Baseline and at designated timepoints up to Week 52
Percentage of Participants Achieving LDA based on DAS28-CRP
Tidsramme: At designated timepoints up to Week 52

The DAS28-CRP is a continuous composite measure of RA disease activity that includes the following components:

  • TJC (out of a total of 28 joints)
  • SJC (out of a total of 28 joints)
  • hsCRP
  • PtGA The 28 anatomical joints for inclusion in the TJC and SJC scoring are the shoulders, elbows, wrists, first through fifth metacarpophalangeals, second through fifth proximal interphalangeals, thumb interphalangeals, and knees. The DAS28-CRP score ranges from 0 to 10, with higher scores indicating a higher degree of disease activity. Remission is indicated by a DAS28-CRP score of <2.6 and LDA by a DAS28-CRP score of ≤3.2. The percentage of participants achieving LDA at designated timepoints up to Week 52 based on DAS28-CRP will be presented.
At designated timepoints up to Week 52
Percentage of Participants Achieving Clinical Remission Based on DAS28-CRP
Tidsramme: At designated timepoints assessed up to Week 52

The DAS28-CRP is a continuous composite measure of RA disease activity that includes the following components:

  • TJC (out of a total of 28 joints)
  • SJC (out of a total of 28 joints)
  • hsCRP
  • PtGA The 28 anatomical joints for inclusion in the TJC and SJC scoring are the shoulders, elbows, wrists, first through fifth metacarpophalangeals, second through fifth proximal interphalangeals, thumb interphalangeals, and knees. The DAS28-CRP score ranges from 0 to 10, with higher scores indicating a higher degree of disease activity. Remission is indicated by a DAS28-CRP score of <2.6 and LDA by a DAS28-CRP score of ≤3.2. The percentage of participants achieving clinical remission at designated timepoints assessed up to Week 52 based on DAS28-CRP will be presented.
At designated timepoints assessed up to Week 52
Change From Baseline in the HAQ-DI Score
Tidsramme: Baseline and Week 12

HAQ-DI is measure of physical function in RA clinical trials and is a 20-item questionnaire completed by the participant. The measure includes 8 domains assessing "dressing and grooming," "arising," "eating," "walking," "hygiene," "reach," "grip," and "activities." Participants respond on a 4-point scale ranging from 0 = "without ANY difficulty" to 3 = "UNABLE to do." The measure also captures the use of aids or devices and need for help from another person. The overall disability score is a summation of the highest score from each domain divided by the number of domains completed and ranges from 0 to 3 (worst disability). Clinically meaningful improvement in HAQ-DI for RA has been determined to be ≥0.22 points. The change from Baseline to Week 12 in the HAQ-DI will be presented.

Baseline and Week 12

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Medical Director, Merck Sharp & Dohme LLC

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

23. november 2026

Primær fullføring (Antatt)

19. oktober 2027

Studiet fullført (Antatt)

28. november 2028

Datoer for studieregistrering

Først innsendt

19. oktober 2026

Først innsendt som oppfylte QC-kriteriene

19. oktober 2026

Først lagt ut (Faktiske)

26. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere